` IOBT (IO Biotech Inc) vs S&P 500 Comparison - Alpha Spread

IOBT
vs
S&P 500

Over the past 12 months, IOBT has underperformed S&P 500, delivering a return of 6% compared to the S&P 500's 9% growth.

Stocks Performance
IOBT vs S&P 500

Loading
IOBT
S&P 500
Add Stock
www.alphaspread.com

Performance Gap
IOBT vs S&P 500

Performance Gap Between IOBT and GSPC
HIDDEN
Show

Performance By Year
IOBT vs S&P 500

Loading
IOBT
S&P 500
Add Stock

Competitors Performance
IO Biotech Inc vs Peers

S&P 500
IOBT
ABBV
AMGN
GILD
VRTX
Add Stock

IO Biotech Inc
Glance View

Market Cap
85.6m USD
Industry
Biotechnology

IO Biotech, Inc. is a clinical stage biotechnology company. The Company’s product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced immunosuppression. IO Biotech’s lead product candidate, IO102-IO103, is designed to target the immunosuppressive mechanisms mediated by key immunosuppressive proteins such as IDO and PD-L1. The firm develops a pipeline of product candidates that leverage its T-win technology platform to address targets within the TME. The firm is spin-off of National Cancer for Center Immune Therapy at Herlev University Hospital in Denmark.

IOBT Intrinsic Value
Not Available
Back to Top